AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00

AnaptysBio (NASDAQ:ANAB) had its price objective upped by HC Wainwright from $51.00 to $66.00 in a research report released on Wednesday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for AnaptysBio’s Q1 2026 earnings at ($1.12) EPS, Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.88) EPS, FY2026 earnings at ($6.52) EPS, FY2027 earnings at ($8.55) EPS, FY2028 earnings at ($3.51) EPS, FY2029 earnings at ($0.61) EPS and FY2030 earnings at $7.67 EPS.

A number of other research firms have also commented on ANAB. Truist Financial lifted their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Barclays lifted their price objective on AnaptysBio from $55.00 to $78.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Stifel Nicolaus lowered their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $73.44.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $55.41 on Wednesday. The firm’s 50 day moving average price is $50.27 and its 200-day moving average price is $39.03. AnaptysBio has a 52-week low of $15.32 and a 52-week high of $63.47. The company has a market cap of $1.59 billion, a PE ratio of -106.56 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The company had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. On average, analysts forecast that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has approved a share repurchase plan on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

Insider Transactions at AnaptysBio

In other news, CFO Dennis Mulroy sold 15,725 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total value of $705,266.25. Following the transaction, the chief financial officer owned 9,401 shares in the company, valued at $421,634.85. This represents a 62.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the transaction, the director directly owned 9,930 shares in the company, valued at approximately $478,923.90. The trade was a 52.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 156,280 shares of company stock worth $7,254,939 in the last ninety days. Insiders own 33.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANAB. Smartleaf Asset Management LLC boosted its stake in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 821 shares during the last quarter. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. raised its holdings in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the period. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its position in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter.

Key Headlines Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.